Dennis Ochoa Barajas - Academia.edu (original) (raw)
Uploads
Papers by Dennis Ochoa Barajas
El banano es el cultivo de mayor importancia económica del Ecuador, constituyendo una de las fuen... more El banano es el cultivo de mayor importancia económica del Ecuador, constituyendo una de las fuentes principales de empleo en el área agrícola.
… Y Abonos Organicos
... Shinde y Ghosh (1971) aplicaron 5.6 t de estiércol vacuno por hectárea por año, durante 10 añ... more ... Shinde y Ghosh (1971) aplicaron 5.6 t de estiércol vacuno por hectárea por año, durante 10 años consecutivos y reportaron incrementos en el contenido de materia orgánica del suelo de 0.12 a 1.98% y un ligero aumento del nitrógeno total. ...
Revista internacional …, 2011
Chapman University Law Research …, 2010
... in Puerto Rico (paper presented at LatCrit-SNX 2010 symposium on The Global Politics of ... g... more ... in Puerto Rico (paper presented at LatCrit-SNX 2010 symposium on The Global Politics of ... gps/id366118028; Sutro Media, Los Angeles Street Food, http://itunes.apple.com/us/app/los ... Webpages tracking trucks include LA Trux Map, LA Food Trucks Map, http://la.truxmap.com ...
Advances in immunology, 2012
…, 2009
Stimulating the innate and adaptive immunity against cancer necessitates the tricking of a system... more Stimulating the innate and adaptive immunity against cancer necessitates the tricking of a system evolved to fight microbial pathogens and directing its activity towards transformed self-tissue. Efficacious interventions to start and sustain the response will probably require a number of agents to tamper simultaneously or sequentially with several immune mechanisms. Although master switches controlling various functions may exist, the goal of a curative immune response will probably demand the combined actions of several therapeutic components. Synergy occurs when drugs interact in ways that enhance or magnify one or more effects or side effects. In cancer immunotherapy, two agents that have minor or no therapeutic effects as single agents can be powerful when combined. Mouse experimentation provides multiple examples of synergistic combinations. Elements to be combined include chiefly: tumor vaccines, adoptive T-cell therapies, cytokines, costimulatory molecules, molecular deactivation of immunosuppressive or tolerogenic pathways and immunostimulatory monoclonal antibodies. These novel therapies, even as single agents, are extremely complex products to be developed owing to the associated biomolecules, cell therapies or gene therapies. At present, drug-development programs are run individually for each immunotherapeutic agent and combinations are considered only at a later stage in clinical development, even in the absence of formal compulsory regulations to prevent clinical trials with combinations. As a result, instead of the search for maximal efficacy, ease of combination with standard treatments, intellectual property management, regulations and business-based decisions often guide the way. Even though the maximal effort must be made in order to prevent adverse effects in patients, it seems reasonable that combination pilot trials should be performed at an early stage, following safe completion of Phase I trials. These trials should be performed based on evidence for synergy in animal models and be simplified in terms of regulatory requirements. Such 'short-cut' combination immunotherapy trials can bring much needed efficacy earlier to the bedside.
Bol Pediatr, 2006
Objetivos: describir la evolución de la infección faríngea por Streptococcus pyogenes en un área ... more Objetivos: describir la evolución de la infección faríngea por Streptococcus pyogenes en un área de salud. Valorar el riesgo en función de la edad y época del año, así como la tendencia de la resistencia a antimicrobianos.
El banano es el cultivo de mayor importancia económica del Ecuador, constituyendo una de las fuen... more El banano es el cultivo de mayor importancia económica del Ecuador, constituyendo una de las fuentes principales de empleo en el área agrícola.
… Y Abonos Organicos
... Shinde y Ghosh (1971) aplicaron 5.6 t de estiércol vacuno por hectárea por año, durante 10 añ... more ... Shinde y Ghosh (1971) aplicaron 5.6 t de estiércol vacuno por hectárea por año, durante 10 años consecutivos y reportaron incrementos en el contenido de materia orgánica del suelo de 0.12 a 1.98% y un ligero aumento del nitrógeno total. ...
Revista internacional …, 2011
Chapman University Law Research …, 2010
... in Puerto Rico (paper presented at LatCrit-SNX 2010 symposium on The Global Politics of ... g... more ... in Puerto Rico (paper presented at LatCrit-SNX 2010 symposium on The Global Politics of ... gps/id366118028; Sutro Media, Los Angeles Street Food, http://itunes.apple.com/us/app/los ... Webpages tracking trucks include LA Trux Map, LA Food Trucks Map, http://la.truxmap.com ...
Advances in immunology, 2012
…, 2009
Stimulating the innate and adaptive immunity against cancer necessitates the tricking of a system... more Stimulating the innate and adaptive immunity against cancer necessitates the tricking of a system evolved to fight microbial pathogens and directing its activity towards transformed self-tissue. Efficacious interventions to start and sustain the response will probably require a number of agents to tamper simultaneously or sequentially with several immune mechanisms. Although master switches controlling various functions may exist, the goal of a curative immune response will probably demand the combined actions of several therapeutic components. Synergy occurs when drugs interact in ways that enhance or magnify one or more effects or side effects. In cancer immunotherapy, two agents that have minor or no therapeutic effects as single agents can be powerful when combined. Mouse experimentation provides multiple examples of synergistic combinations. Elements to be combined include chiefly: tumor vaccines, adoptive T-cell therapies, cytokines, costimulatory molecules, molecular deactivation of immunosuppressive or tolerogenic pathways and immunostimulatory monoclonal antibodies. These novel therapies, even as single agents, are extremely complex products to be developed owing to the associated biomolecules, cell therapies or gene therapies. At present, drug-development programs are run individually for each immunotherapeutic agent and combinations are considered only at a later stage in clinical development, even in the absence of formal compulsory regulations to prevent clinical trials with combinations. As a result, instead of the search for maximal efficacy, ease of combination with standard treatments, intellectual property management, regulations and business-based decisions often guide the way. Even though the maximal effort must be made in order to prevent adverse effects in patients, it seems reasonable that combination pilot trials should be performed at an early stage, following safe completion of Phase I trials. These trials should be performed based on evidence for synergy in animal models and be simplified in terms of regulatory requirements. Such 'short-cut' combination immunotherapy trials can bring much needed efficacy earlier to the bedside.
Bol Pediatr, 2006
Objetivos: describir la evolución de la infección faríngea por Streptococcus pyogenes en un área ... more Objetivos: describir la evolución de la infección faríngea por Streptococcus pyogenes en un área de salud. Valorar el riesgo en función de la edad y época del año, así como la tendencia de la resistencia a antimicrobianos.